Harrington Heart & Vascular Institute

Wednesday, January 18, 2017

Call for Scholars: Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute expand collaboration

CLEVELAND – Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) are pleased to announce a request for proposals for the 2017 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award supports breakthrough research that promises to prevent, treat or cure Alzheimer’s disease, related dementias and cognitive aging.
 
Applicants have the opportunity to receive:
  • Financial support up to $600,000 over two years
  • Drug development and project management support through Harrington Discovery Institute’s Innovation Support Center
Research without walls: 
“This is a superb opportunity for creative researchers who seek a cure for Alzheimer’s and other dementias,” said Jonathan Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine. “The ADDF-Harrington partnership brings a unique combination of knowhow and resources to advance the most innovative discoveries in Alzheimer’s disease.” 
 
“Our collaboration with Harrington Discovery Institute provides Alzheimer’s researchers critical support needed to move discoveries into clinical trials,” said Howard Fillit, MD, Founding Executive Director and Chief Science Officer at the ADDF. “The impact of Alzheimer’s disease is enormous. We need new and diverse approaches to make a difference—and our partnership with Harrington Discovery Institute exemplifies our commitment to advancing these.”
 
Award criteria:
  • The competition is open to academic investigators at accredited medical centers, research institutions and universities in the United States
  • Lead investigator must have an MD or PhD (or equivalent)
  • Proposals should offer creative science or approach to treat, prevent or slow Alzheimer’s disease, other dementias or cognitive aging
 
Please note the following dates:
  • Letters of Intent will be accepted through March 17, 2017
  • Up to 3 awards will be announced by the end of October
  • Applications must be submitted online at AlzDiscovery.org/RFPs
 
 
For more information, please visit HarringtonDiscovery.org/ADDF or AlzDiscovery.org.
 


Thursday, January 12, 2017

Harrington Discovery Institute at University Hospitals announces 2017 grant funding to 11 physician-scientists

CLEVELAND –  The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, has announced the 2017 recipients of Harrington Scholar-Innovator Awards. The awards support breakthrough discoveries of physician-scientists whose research shows promise to advance the standard of care.
 
The Harrington Discovery Institute – part of The Harrington Project for Discovery & Development –fulfills an unmet need in academic medicine: to advance early breakthroughs into the clinical realm. Its focus on physician-scientist innovators from across the country and the UK creates opportunity to transform the best innovation regardless of institution affiliation.      
 
In addition to financial support awarded to the winners, the Institute provides direction from leaders in the pharmaceutical industry who are charged with overseeing therapeutic development of Scholar programs. While working with the Institute, physician-scientists (and their institutions) retain the intellectual property for their work.
 
“Our scholars tell us that the guidance they receive from members of the Harrington Innovation Support Center is absolutely the most valuable part of their time with us—of even greater value than the money,” said Jonathan Stamler, MD, President of the Harrington Discovery Institute. “Research institutions and non-profit endeavors do not typically provide strong pharmaceutical capability. Technology languishes for lack of know-how.  We believe that if we can marry the best science with the best practices, we should be able to more effectively advance discovery.”
 
The selected scholars have access to several rounds of capital (up to a total of $700,000) through their affiliation with the Harrington Discovery Institute to support the transition of their work into the private sector. Scholars are then free to approach investors of their choice to underwrite the commercialization of their work or they can have facilitated access to BioMotiv, the mission-aligned development company that also is part of The Harrington Project. However, there are no obligations on either side.  
 
The 2017 Harrington Scholar-Innovator grant recipients are:
 
Paul Bollyky, MD, PhD – Stanford University – A novel drug for Type I Diabetes
 
Ambrose Cheung, MD – Geisel School of Medicine at Dartmouth – A novel treatment against MRSA and other Gram+ bacterial infections
 
Giulio Draetta, MD, PhD – The University of Texas MD Anderson Cancer Center – A new therapy and first in-human trials for pancreatic cancer
 
Seth Field, MD, PhD – University of California San Diego – A novel pathway causing cancer
 
Todd Gould, MD – University of Maryland – A new medicine for depression
 
John Letterio, MD – Case Western Reserve University/University Hospitals – A promising drug for Alzheimer’s disease, stroke and cancer
 
David Lombard, MD, PhD – University of Michigan – A new strategy in melanoma therapy
 
Daruka Mahadevan, MD, PhD – University of Arizona – A novel class of cancer drugs and radiation sensitizers
 
Deepak Nijhawan, MD, PhD


Thursday, January 12, 2017

Harrington Discovery Institute announces 2016 Partnership Scholars

CLEVELAND – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – has announced its 2016 partnership Scholars selected in collaboration with Alzheimer’s Drug Discovery Foundation (ADDF), and Foundation Fighting Blindness and University of Oxford.
 
Harrington Discovery Institute collaborations are based on a shared mission to advance discoveries into new medicines that will improve human health, as well as, enhance each organization's ability to play a significant role in setting the scientific and innovation agenda in leading-edge research.  These awards offer selected winners funding and expert pharmaceutical guidance to move their discoveries forward and ensure the most promising enter the clinic. Please join us in congratulating our newest scholars.
 
The 2016 ADDF-Harrington Scholars are: 
·         Travis Dunckley, PhD, Arizona State University, whose work focuses on using DYRK1A inhibitors to prevent cognitive impairment and Alzheimer’s pathology
·         Sung Ok Yoon, PhD, The Ohio State University, whose work focuses on using novel inhibitors of a stress-activated kinase for the treatment of Alzheimer’s disease
 
The 2016 Gund-Harrington Scholar is:
  • David M. Gamm, MD, PhD, University of Wisconsin-Madison, whose work focuses on restoring sight through the use of human pluripotent stem cells in individuals suffering from retinal degenerative disease
 
The 2016 Oxford-Harrington Scholar is: 
  • Valentine M. Macaulay, MD, PhD, whose work focuses on disrupting receptor internalization and nuclear translocation as a novel therapy for cancer
 
“The Cleveland-based Harrington Discovery Institute currently supports promising discoveries in North America and the U.K.,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute. “Our collaborations with disease foundations and like-minded research institutions allow us to better address underserved areas of medicine and to bring forth new medicines where treatments remain elusive.”    
 
“We at the Foundation Fighting Blindness continue to applaud Ron Harrington’s support for accelerating promising research from the bench to clinical studies,” said Gordon Gund, chairman and co-founder of the Foundation Fighting Blindness. “The Harrington Discovery Institute offers highly pragmatic support to our researchers, based in hundreds of years of collective experience from an impressive cadre of pharmaceutical R&D executives. Together we are dedicated to helping millions defeat diseases that limit the ability to experience the gift of sight.”
 
In addition to funding, award recipients receive committed drug development and project management support through the Harrington Discovery Institute’s Innovation Support Center for the duration of the term of the award. This includes consulting and management services from experienced pharmaceutical development professionals, as well as regulatory, intellectual property and business development assistance. 
 
“I am delighted that Professor Macaulay has been selected as the next Oxford-Harrington Scholar,” said Professor Sir John Bell, Regius Professor of Medicine, University of Oxford. “This program will support her novel approach around hormone receptors, which shows promise in treating cancers that touch millions of lives around the world.”
 
Harrington Scho


Tuesday, January 10, 2017

Harrington Discovery Institute and Alzheimer’s Drug Discovery Foundation expand collaboration

CLEVELAND – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio and the Alzheimer’s Drug Discovery Foundation (ADDF) have expanded their collaboration to accelerate translation of innovative research efforts for Alzheimer’s disease. Together, the two organizations will jointly market and administer a new award program for academic researchers. By leveraging their combined expertise, investment, and resources, Harrington Discovery Institute and the ADDF will advance Alzheimer’s disease drug discovery projects of great promise in academic institutions nationwide.
 
“We are so pleased to enhance our partnership with the ADDF and further support groundbreaking Alzheimer’s disease research,” commented Dr. Jonathan Stamler, MD, President, Harrington Discovery Institute. “Millions of patients and families in the US and around the world are eager for effective treatments. The ADDF has shown a sense of urgency that has made us a better organization, and we share their commitment to advancing neurological discoveries of great promise.”  
 
The keystone of the collaboration is the ADDF-Harrington Scholar Award, which provides funding and drug development support to both MD and PhD scientists across the United States, to help advance discovery into the clinical realm. In addition to financial support of up to $600,000, ADDF-Harrington Scholars also receive hands-on direction from pharmaceutical industry leaders in Harrington Discovery Institute’s Innovation Support Center, who have extensive experience bringing research to the market. ADDF-Harrington Scholars also have facilitated access to BioMotiv, the mission-driven development company associated with The Harrington Project.


Friday, January 06, 2017

Most younger adults with high LDL-C levels do not take a statin

CLEVELAND – Despite recommendations, less than 45 percent of adults younger than 40 years with an elevated low-density lipoprotein cholesterol (LDL-C) level of 190 mg/dL or greater receive a prescription for a statin, according to a study published online by JAMA Cardiology.
 
Cardiovascular disease affects 1 in 3 patients and remains the leading cause of death in the United States. Severe elevation of LDL-C levels is a modifiable risk factor for developing premature cardiovascular disease. Treatment with statins is recommended for all adults 21 years or older with an LDL-C of 190 mg/dL or greater, with treatment appearing to reduce the risk of death and result in cost savings for health systems.



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.